Hepatocellular carcinoma incidence trends in Canada: Analysis by birth cohort and period of diagnosis

Liver International

Volumn 28, Issue 9, 2008, Pages 1272-1279

  Pocobelli, Gaia ^a,e   Cook, Linda S ^b   Brant, Rollin ^c   Lee, Samuel S ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Age period cohort; Birth cohort; Canada; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIRTH; CANADA; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MALE; PERIODICITY; SEX DIFFERENCE; TREND STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CANADA; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FORECASTING; HUMANS; INCIDENCE; LIKELIHOOD FUNCTIONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 51649112943     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01704.x     Document Type: Article

References (28)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. Cancer J Clin 2005; 55: 10-30.
4. Kew MC. Hepatic tumors and cysts. In: Feldman MSM, Scharschmidt BF, eds. Sleisenger's and Fordtrans's Gastrointestinal and Liver Disease. Philadephia: WB Saunders, 1998; 1364-87.
5. elSaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002; 93: 443-6.
6. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-6.
7. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
8. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817-23.
9. Benhamiche AM, Faivre C, Minello A, et al. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 1998; 29: 802-6.
10. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust 2000; 173: 403-5.
11. London WT, McGlynn K Liver cancer. In Fraumeri JF, Schottenfield D, eds Cancer Epidemiology and Prevention. New York: Oxford University Press, 1997; 772-93.
12. Health Canada. Blood-borne pathogens routine surveillance system report. Can Commun Dis Rep 2002; 28 (Suppl. 2): 1-59.
13. Sung MW, Thung SN, Acs G. Hepatitis viruses. In: Bast RC, Kufe R, Pollack RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine. London: BC Decker Inc., 2000; 266-76.
14. Statistics Canada. Canadian Cancer Registry (Survey number 3207): http://www.statcan.ca/english/sdds/3207.htm
15. Statistics Canada. Estimates of population by age and sex for Canada, the Provinces and the Territories (Survey number 3604): http://www.statcan.ca/english/sdds/3604.htm.
16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.
17. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987; 6: 449-67.
18. Tarone RE, Chu KC. Evaluation of birth cohort patterns in population disease rates. Am J Epidemiol 1996; 143: 85-91.
19. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987; 6: 469-81.
20. Chu KC. Re: Temporal trends in diabetes mortality among American Indians and Hispanics in New Mexico: Birth cohort and period effects. Am J Epidemiol 1998; 147: 796-800.
21. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107, vi.
22. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12 (Part 1): 671-5.
23. Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-54.
24. Yu MW, Cheng SW, Lin MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 2023-8.
25. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N Engl J Med 1997; 336: 1855-9.
26. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-30.
27. Kulkarni K, Barcak E, El-Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2004; 20: 445-50.
28. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol 2005; 23: 2892-9.